IONIS PHARMACEUTICALS INC (IONS) Stock News

USA - NASDAQ:IONS - US4622221004 - Common Stock

73.09 USD

+0.02 (+0.03%)

Last: 10/17/2025, 8:21:10 PM

73.09 USD

0 (0%)

After Hours: 10/17/2025, 8:21:10 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IONS Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill

News Image

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength

3 days ago - By: Benzinga

31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know

3 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis to hold third quarter 2025 financial results webcast

11 days ago - By: Investor's Business Daily - Mentions: GILD

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike

11 days ago - By: Benzinga - Mentions: BOKF PEN OTIS

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

12 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

26 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

a month ago - By: Stocktwits - Mentions: EAOR PBE

News Image

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

a month ago - By: Ionis Pharmaceuticals, Inc.

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

a month ago - By: Biogen Inc. - Mentions: BIIB

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

a month ago - By: Zacks Investment Research - Mentions: RARE ADPT AKRO

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis to host investors and analysts for Innovation Day 2025

2 months ago - By: Yahoo Finance

Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results

2 months ago - By: Zacks Investment Research - Mentions: AZN GSK BIIB

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis to present at upcoming investor conferences

2 months ago - By: Stocktwits - Mentions: EAOR AVSU

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies

2 months ago - By: Investor's Business Daily

Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.

2 months ago - By: Ionis Pharmaceuticals, Inc.

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

2 months ago - By: Yahoo Finance - Mentions: JPM

J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating

2 months ago - By: Stocktwits

News Image

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

2 months ago - By: Ionis Pharmaceuticals, Inc.

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

3 months ago - By: Yahoo Finance - Mentions: MS NVDA

Why Morgan Stanley Upgraded This Biotech Stock to a Buy